Ocugen, Inc.

Stocks

OCGN

US67577C1053

Market Closed - Nasdaq Other stock markets 01:30:00 13/06/2026 am IST			5-day change	1st Jan Change
1.210 ^USD	-0.82%		-5.47%	-10.37%

04/06	Ocugen, Inc. Announces Executive Changes, Effective May 29, 2026	CI
15/05	Ocugen Closes Offering of Senior Notes Due 2034	MT

Transcript : Ocugen, Inc., Q1 2026 Earnings Call, May 05, 2026

Published on 05/06/2026 at 12:20 am IST - Modified on 05/08/2026 at 03:58 pm IST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, and welcome to Ocugen First Quarter 2026 Financial Results and Business Update. [Operator Instructions] I will now turn the call over to

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Ocugen, Inc.

04/06	Ocugen, Inc. Announces Executive Changes, Effective May 29, 2026	CI
15/05	Ocugen Closes Offering of Senior Notes Due 2034	MT
15/05	Ocugen, Inc. Announces Chief Medical Officer Changes, Effective May 8, 2026	CI
06/05	Ocugen, Inc., Q1 2026 Earnings Call, May 05, 2026
05/05	Ocugen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05/05	Ocugen Prices $115 Million Convertible Senior Notes Offering	MT
05/05	Ocugen, Inc. announces pricing of $115 million of 6.75% convertible senior notes	RE
10/04	Ocugen, Inc. Announces Modifier Gene Therapy Delivers 46% Lesion Reduction in Age-Related Macular Degeneration	CI
01/04	Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of Ocu410st for Stargardt Disease	CI
01/04	Ocugen Completes Enrollment, Dosing for Phase 2/3 Eye Disorder Treatment Trial; Shares Up Pre-Bell	MT
24/03	Ocugen, Inc. - Special Call
24/03	Ocugen Inc Announces Topline 12-Month Data from Phase 2 Armada Clinical Trial Evaluating Ocu410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration	CI
24/03	Ocugen Reports Positive Phase 2 Trial Data For Eye Disease Therapy	MT
23/03	Ocugen, Inc.(NasdaqCM:OCGN) added to S&P Biotechnology Select Industry Index	CI
17/03	Canaccord Genuity Initiates Ocugen at Buy With $12 Price Target	MT